Clinical Trials List
2021-12-20 - 2031-03-31
Phase III
Recruiting8
ICD-10C64.1
Malignant neoplasm of right kidney, except renal pelvis
ICD-10C64.2
Malignant neoplasm of left kidney, except renal pelvis
ICD-10C64.9
Malignant neoplasm of unspecified kidney, except renal pelvis
ICD-10C7A.093
Malignant carcinoid tumor of the kidney
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9189.0
Malignant neoplasm of kidney, except pelvis
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- William Huang Division of Urology
- 陳威任 Division of Urology
- I-Shen Huang Division of Urology
- 彭昱璟 Division of Others
- Yi-Hsiu Huang Division of Urology
- Tzu-chun Wei Division of Urology
- Ming-Hsuan Ku Division of Urology
- Tzu-Ping Lin 無
- Chih-Chieh Lin Division of Urology
- Jia-An Hong Division of Radiology
- Yen-Hwa Chang Division of Urology
- Tzu-Hao Huang Division of Urology
- Yu-Hua Fan Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chuan-Shu Chen Division of Urology
- Chia-Yen Lin Division of Urology
- 張瓈文 Division of Urology
- 林雁婷 Division of Radiology
- 裘坤元 Division of Urology
- 盧嘉文 無
- 梅承恩 Division of Urology
- 廖博崎 無
- Jian-Ri Li Division of Urology
- Cheng-Che Chen Division of Urology
- 王樹吉 Division of Urology
- JU-CHUAN HU Division of Urology
- Cheng-Kuang Yang Division of Urology
- 洪晟鈞 Division of Urology
- 賴谷順 Division of Urology
- 張文 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 闕士傑 Division of Urology
- YI-KAI CHANG Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- YEN-HENG LIN Division of Radiology
- - - Division of Urology
- JIAN-HUA HONG Division of Urology
- FU-JEN HSUEH Division of Hematology & Oncology
- 洪建華 無
- Yeong-Shiau Pu Division of Urology
- PO-MING CHOW Division of Urology
- 曾啟新 Division of Urology
- CHING-CHU LU Division of Nuclear Medicine
- - - Division of Urology
- YU-CHUAN LU Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- 王中傑 Division of Others
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- See-Tong Pang Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- PO-HUNG LIN Division of Hematology & Oncology
- 黃亮鋼 Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- 黃俊德 無
- Po-Jung Su Division of Hematology & Oncology
- 沈鼎文 Division of Radiology
- Hong-Cheng Gan Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- Rita cheng 無
- Yuan-Cheng Chu 無
- Yung-Chia Kao Division of Hematology & Oncology
- 吳俊德 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chao-Hsiang Chang Division of Urology
- Po-Jen Hsiao Division of Urology
- 賴俊佑 Division of Urology
- 鄭富銘 Division of Hematology & Oncology
- Hsi-Chin Wu Division of Urology
- 陳冠亨 Division of Urology
- Yu-De Wang Division of Urology
- Ching-Chan Lin Division of Hematology & Oncology
- Wei-Ching Lin Division of Radiology
- Po-Fan Hsieh Division of Urology
- 邱鴻傑 Division of Urology
- Su-Peng Yeh Division of Hematology & Oncology
- Han Chang Division of General Surgery
- Chi-Rei Yang Division of Urology
- Yi-Huei Chang Division of Urology
- 蔡禮賢 Division of Urology
- Che-Hung Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
1800 participants
